A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Conference item |
Published: |
Oxford University Press
2016
|
_version_ | 1797082077216112640 |
---|---|
author | Pacey, S Blackhall, F Garcia-Corbacho, J Lipplaa, A Fusi, A Kumar, S Hategan, M Derham, J Laviste, G Halford, S Foxton, C McLeod, R Wan, S Talbot, D |
author_facet | Pacey, S Blackhall, F Garcia-Corbacho, J Lipplaa, A Fusi, A Kumar, S Hategan, M Derham, J Laviste, G Halford, S Foxton, C McLeod, R Wan, S Talbot, D |
author_sort | Pacey, S |
collection | OXFORD |
description | |
first_indexed | 2024-03-07T01:23:06Z |
format | Conference item |
id | oxford-uuid:9108ca55-a19b-4f53-a76d-065fd4d411df |
institution | University of Oxford |
last_indexed | 2024-03-07T01:23:06Z |
publishDate | 2016 |
publisher | Oxford University Press |
record_format | dspace |
spelling | oxford-uuid:9108ca55-a19b-4f53-a76d-065fd4d411df2022-03-26T23:15:51ZA phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumorsConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:9108ca55-a19b-4f53-a76d-065fd4d411dfSymplectic Elements at OxfordOxford University Press2016Pacey, SBlackhall, FGarcia-Corbacho, JLipplaa, AFusi, AKumar, SHategan, MDerham, JLaviste, GHalford, SFoxton, CMcLeod, RWan, STalbot, D |
spellingShingle | Pacey, S Blackhall, F Garcia-Corbacho, J Lipplaa, A Fusi, A Kumar, S Hategan, M Derham, J Laviste, G Halford, S Foxton, C McLeod, R Wan, S Talbot, D A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors |
title | A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors |
title_full | A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors |
title_fullStr | A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors |
title_full_unstemmed | A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors |
title_short | A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors |
title_sort | phase i dose escalation study of the tolerability of the oral vegfr and egfr inhibitor vandetanib in combination with the oral mek1 2 inhibitor selumetinib in solid tumors |
work_keys_str_mv | AT paceys aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT blackhallf aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT garciacorbachoj aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT lipplaaa aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT fusia aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT kumars aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT hateganm aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT derhamj aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT lavisteg aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT halfords aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT foxtonc aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT mcleodr aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT wans aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT talbotd aphaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT paceys phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT blackhallf phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT garciacorbachoj phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT lipplaaa phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT fusia phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT kumars phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT hateganm phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT derhamj phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT lavisteg phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT halfords phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT foxtonc phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT mcleodr phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT wans phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors AT talbotd phaseidoseescalationstudyofthetolerabilityoftheoralvegfrandegfrinhibitorvandetanibincombinationwiththeoralmek12inhibitorselumetinibinsolidtumors |